TAmiRNA brings new musculoskeletal insights to ECTS 2018

TAmiRNA brings new musculoskeletal insights to ECTS 2018


Press Release | TAmiRNA GmbH

MAY 16, 2018

Vienna, Austria: – Biotech innovators TAmiRNA is returning to the European Calcified Tissue Society (ECTS) Congress to present its latest scientific insights on microRNA biomarkers for bone disease.

TAmiRNA will be exhibiting at the congress from Booth 15 at the Valencia Conference Center in Spain. The display will feature the osteomiR diagnostic kits that enable rapid detection of microRNAs that could serve as novel validated bone biomarker for early diagnosis and prognosis of fracture risk in post-menopausal osteoporosis and bone quality.

TAmiRNA will also present high-quality analytical services in compliance with the high standards required by diagnostics development.

Scientific contribution

TAmiRNA co-founder Dr. Johannes Grillari and 2 scientific groups, working in cooperation with TAmiRNA will also present posters and scientific insights at the Congress.

On the opening day of the congress, TAmiRNA co-founder Dr. Johannes Grillari, will talk on ‘iPSC and organoid Technology’ in Auditorium 2 during the morning session.

On Day Two, Dr. Riikka Mäkitie will share insights on ‘Altered MicroRNA profile in osteoporosis caused by impaired WNT signaling’ (Poster number: P061, Poster Loft 26) supported by discussion in Auditorium 2 during the evening session.

On Day Three, Dr. Patryk Zarecki will present results on using ‘miRNAs as biomarkers for osteoporotic vertebral fractures’ (Poster number: P090, Poster Loft 26).

Novel validated biomarkers

TAmiRNA will also be represented at the event by Dr. Matthias Hackl, CEO, with osteomiR Product Manager, Dr. Hanna Dellago.

“We have been attending ECTS for many years,” said Dr. Hackl. “This is an excellent forum for researchers and clinicians working in the musculoskeletal field to discover and discuss the latest advances and controversies in research and in the daily care of patients.”

“It provides a great platform for us to share new scientific results on novel validated bone biomarkers for predicting fracture risk along with new ways of identifying high-risk subsets that qualify for preventive therapeutic treatment with an eminent professional audience,” he added.

About TAmiRNA

Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.

TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular and metabolic diseases (thrombomiR).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.

More information available at: www.tamirna.com.

About ECTS 2018

The European Calcified Tissue Society (ECTS) is the major organization in Europe for researchers and clinicians working in the musculoskeletal field. The society’s annual meeting serves as a forum for the dissemination of scientific excellence and education in musculoskeletal medicine.

ECTS represents basic researchers, clinicians, students and health allied professionals and is part of a network of more than network of over 30 national and international societies.

The 45th European Calcified Tissue Society Congress, ECTS 2018, is a four-day event opening May 26 at the Valencia Conference Center in Spain.

The event is organized by the European Calcified Tissue Society with further information at: www.ects2018.org/.

Media Contact

Dr. Elisabeth Schraml, Scientific Communications, TAmiRNA GmbH
Tel: +43 (0)660 420 58 56
Email: office@tamirna.com


Click on TAmiRNA at ECTS 2018 for other information.
Click on TAmiRNA to contact the company directly.
Click on Science Direct for full study article.

Dr. Matthias Hackl, CEO, TAmiRNA GmbH

Dr. Matthias Hackl, CEO, TAmiRNA GmbH

Product Manager, Dr. Hanna Dellago

Product Manager, Dr. Hanna Dellago

Supplier Information
Supplier: TAmiRNA GmbH
Address: Muthgasse 18, 1190 Vienna, Austria
Tel: +43 (0)660 420 58 56
Website: www.tamirna.com

Comments are closed.